Metric Bio’s Post

Thoughts on this? >> Exa-Cel Shows Long-Term Clinical Benefit in Sickle Cell Disease, TDT - MD Magazine >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #pharmaceutical #competitivemarketing #healthcare #biotech

Thoughts on this? >> Cabaletta's 2-patient CAR-T data hint at autoimmune remission, but investors want more >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #pharma #biotech #pharmaceutical #competitivemarketing

#News: AbbVie has announced that it will be expanding its inflammatory and autoimmune disease portfolio by acquiring Landos Biopharma, Inc. for up to $212.5m. #Landos is a #clinicalstage #biopharmaceutical company that focuses on the development of #oraltherapeutics for patients with #autoimmunediseases. Inflammatory conditions such as #inflammatoryboweldisease (IBD) cause excess inflammation, while the body’s natural defence system mistakenly attacks normal cells as opposed to foreign cells in autoimmune diseases. In some conditions, including #rheumatoidarthritis and #lupus, both autoimmune and inflammatory diseases play a role when #antibodies get directed against the body’s own cells, causing inflammation. Under the terms of the agreement, #AbbVie will acquire Landos for approximately $137.5m, plus an additional $75m, subject to its achievement of a clinical development milestone. Meanwhile, AbbVie will gain rights to advance the clinical development of Landos’ lead investigational asset, NX-13, as a potential treatment for patients living with #ulcerativecolitis (UC) and #Crohnsdisease, two forms of IBD. Read more from PM LIVE 👇🏼 https://lnkd.in/gjEG_DW4

Thoughts on this? >> Exa-Cel Shows Long-Term Clinical Benefit in Sickle Cell Disease, TDT - MD Magazine >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #competitivemarketing #healthcare #pharmaceutical #pharma

Study results Phase III APPEAR-C3G study showing that its oral factor B inhibitor iptacopan significantly reduced protein in the urine of patients with C3 glomerulopathy, an ultra-rare and progressive kidney disease #oncology #kidneycancer #novartis #innovation #clinicalresearchassociate #clinicaltrials #phase3 #raredisease #iptacopan #outsourcingsolutions

Thoughts on this? >> Cabaletta's 2-patient CAR-T data hint at autoimmune remission, but investors want more >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #competitivemarketing #pharma #pharmaceutical #healthcare #biotech

Lilly Acquires Morphic to Advance IBD Treatments! 🚀💊 Exciting news in the pharmaceutical world! Eli Lilly and Company is set to acquire Morphic Therapeutics for $57 per share. This strategic move gives Lilly acess to Morphic’s portfolio of oral integrin based therapies, and lead asset, a selective small molecule inhibitor of α4β7 integrin (MORF-057), currently being evaluated in multiple IBD indications including ulcerative colitis and Chrohn's. This acquisition is aimed at improving patient outcomes and expanding new treatment options for chronic inflammatory conditions and gastrointestinal disease. Lilly’s mission to tackle significant health challenges continues to drive pioneering medical advancements. By integrating Morphic’s technology, Lilly has eyes set on accelerating the delivery of transformative therapies for IBD in the years to come. Link: https://lnkd.in/gDvwVVdm

Latest Healthcare News & Updates: Immutep Limited Announces Promising Outcomes for First-Line Treatment in PD-L1 Negative Head and Neck Squamous Cell Carcinoma Patients Pfizer Makes Strides in Developing Once-Daily Oral GLP-1 Agonist Danuglipron FDA Issues Complete Response Letter to Novo Nordisk for Once-Weekly Basal Insulin Icodec Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT)' ZORYVE® Cream 0.15% Gains FDA Approval for Atopic Dermatitis Treatment in Adults and Children Aged 6 and Up NICE Recommends Ebglyss For Managing Moderate To Severe Atopic Dermatitis in NHS England's Eligible Adolescent and Adult Population Get more detailed analysis, at: https://lnkd.in/gaUvRwtr #lifesciences #pharmaceuticals #marketresearch #marketanalysis #healthcare #markettrends #health #medical #news #healthcarenews #pharmanews #clinicaltrials #clinicalresearch

89bio begins phase 3 ENLIGHTEN trial to evaluate safety of pegozafermin in patients with metabolic dysfunction-associated steatohepatitis

PNH is characterized by red blood cell destruction, bone marrow failure, and thrombosis. Current existing treatments may leave symptoms uncontrolled, and Fabhalta offers a promising oral alternative. Clinical trials showed increased hemoglobin levels in most patients, with a significant reduction in the need for blood transfusions. The approval is based on the Phase III APPLY-PNH trial, demonstrating Fabhalta's superiority over anti-C5 treatments in hemoglobin improvement. Fabhalta by Novartis is expected to be available in the U.S. in December, with additional regulatory filings underway globally. Another step into challenging rare disease space ! #marketintelligence #competitiveintelligence #marketsmind #novartis #pharmaceutical #fabhalta